Sangamo Therapeutics, Inc.

NASDAQ:SGMO

2.71 (USD) • At close November 12, 2024
Bedrijfsnaam Sangamo Therapeutics, Inc.
Symbool SGMO
Munteenheid USD
Prijs 2.71
Beurswaarde 564,278,910
Dividendpercentage 0%
52-weken bereik 0.3 - 3.18
Industrie Biotechnology
Sector Healthcare
CEO Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Website https://www.sangamo.com

An error occurred while fetching data.

Over Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used

Vergelijkbare Aandelen

The Pennant Group, Inc. logo

The Pennant Group, Inc.

PNTG

33.65 USD

Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc.

FHTX

8.86 USD

Castle Biosciences, Inc. logo

Castle Biosciences, Inc.

CSTL

32.78 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

6.61 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Cullinan Oncology, Inc. logo

Cullinan Oncology, Inc.

CGEM

16.02 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)